Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptau153cxa

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	SEP 01	New pricing for the Save Answers for SciFinder Wizard within STN Express with Discover!
NEWS	4	OCT 28	KOREAPAT now available on STN
NEWS	5	NOV 30	PHAR reloaded with additional data
NEWS	6	DEC 01	LISA now available on STN
NEWS	7	DEC 09	12 databases to be removed from STN on December 31, 2004
NEWS	8	DEC 15	MEDLINE update schedule for December 2004
NEWS	9	DEC 17	ELCOM reloaded; updating to resume; current-awareness alerts (SDIs) affected
NEWS	10	DEC 17	COMPUAB reloaded; updating to resume; current-awareness alerts (SDIs) affected
NEWS	11	DEC 17	SOLIDSTATE reloaded; updating to resume; current-awareness alerts (SDIs) affected
NEWS	12	DEC 17	CERAB reloaded; updating to resume; current-awareness alerts (SDIs) affected
NEWS	13	DEC 17	THREE NEW FIELDS ADDED TO IFIPAT/IFIUDB/IFICDB
NEWS	14	DEC 30	EPFULL: New patent full text database to be available on STN
NEWS	15	DEC 30	CAPLUS - PATENT COVERAGE EXPANDED
NEWS	16	JAN 03	No connect-hour charges in EPFULL during January and February 2005
NEWS	17	FEB 25	CA/CAPLUS - Russian Agency for Patents and Trademarks (ROSPATENT) added to list of core patent offices covered
NEWS	18	FEB 10	STN Patent Forums to be held in March 2005
NEWS	19	FEB 16	STN User Update to be held in conjunction with the 229th ACS National Meeting on March 13, 2005
NEWS	20	FEB 28	PATDPAFULL - New display fields provide for legal status data from INPADOC
NEWS	21	FEB 28	BABS - Current-awareness alerts (SDIs) available
NEWS	22	FEB 28	MEDLINE/LMEDLINE reloaded
NEWS	23	MAR 02	GBFULL: New full-text patent database on STN
NEWS	24	MAR 03	REGISTRY/ZREGISTRY - Sequence annotations enhanced
NEWS	25	MAR 03	MEDLINE file segment of TOXCENTER reloaded

NEWS EXPRESS JANUARY 10 CURRENT WINDOWS VERSION IS V7.01a, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 10 JANUARY 2005

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 16:38:53 ON 17 MAR 2005

=> file caplus uspatful japio epfull medline biosis embase scisearch
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 0.21 0.21

FILE 'CAPLUS' ENTERED AT 16:39:12 ON 17 MAR 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 16:39:12 ON 17 MAR 2005
CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'JAPIO' ENTERED AT 16:39:12 ON 17 MAR 2005
COPYRIGHT (C) 2005 Japanese Patent Office (JPO)- JAPIO

FILE 'EPFULL' ENTERED AT 16:39:12 ON 17 MAR 2005
COPYRIGHT (C) 2005 European Patent Office / FIZ Karlsruhe

FILE 'MEDLINE' ENTERED AT 16:39:12 ON 17 MAR 2005

FILE 'BIOSIS' ENTERED AT 16:39:12 ON 17 MAR 2005
Copyright (c) 2005 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 16:39:12 ON 17 MAR 2005
COPYRIGHT (C) 2005 Elsevier Inc. All rights reserved.

FILE 'SCISEARCH' ENTERED AT 16:39:12 ON 17 MAR 2005
Copyright (c) 2005 The Thomson Corporation

=> s (taxane or paclitaxel or docetaxel)
L1 63912 (TAXANE OR PACLITAXEL OR DOCETAXEL)

=> s l1 and microemulsi?
L2 752 L1 AND MICROEMULSI?

=> s l2 and hydrophobic and (phase or component or layer)
L3 508 L2 AND HYDROPHOBIC AND (PHASE OR COMPONENT OR LAYER)

=> s l3 and (triglyceride or diglyceride or monglyceride or (free fatty acid) or (fatty acid ester) or (fish oil) or (vegetable oil))
6 FILES SEARCHED...
L4 71 L3 AND (TRIGLYCERIDE OR DIGLYCERIDE OR MONGLYCERIDE OR (FREE FATTY ACID) OR (FATTY ACID ESTER) OR (FISH OIL) OR (VEGETABLE OIL))

=> s l4 and (nonionic surfactant#)
L5 11 L4 AND (NONIONIC SURFACTANT#)

=> s l5 and (diethylene glycol monoethylether)
L6 0 L5 AND (DIETHYLENE GLYCOL MONOETHYLETHER)

```
=> s l5 and hydrophilic and (phase or layer or component)
L7          11 L5 AND HYDROPHILIC AND (PHASE OR LAYER OR COMPONENT)

=> s l7 and (hydroxyalkane or dihydroxyalkane or (polyethylen glycol))
<------User Break------>

SEARCH ENDED BY USER

=> s l7 and (hydroxyalkane or dihydroxyalkane or (polyethylene glycol))
L8          11 L7 AND (HYDROXYALKANE OR DIHYDROXYALKANE OR (POLYETHYLENE GLYCO
               L))

=> s l8 and bioavail?
L9           5 L8 AND BIOAVAIL?

=> d l9 1-5 ibib abs

L9   ANSWER 1 OF 5  USPATFULL on STN
ACCESSION NUMBER:        2004:101671  USPATFULL
TITLE:                   Compositions and methods for modulating physiology of
                         epithelial junctional adhesion molecules for enhanced
                         mucosal delivery of therapeutic compounds
INVENTOR(S):             Quay, Steven C., Edmonds, WA, UNITED STATES
PATENT ASSIGNEE(S):      Nastech Pharmaceutical Company Inc. (U.S. corporation)

                              NUMBER        KIND    DATE
                         ---------------- ------ --------
PATENT INFORMATION:      US 2004077540      A1   20040422
APPLICATION INFO.:       US 2003-601953     A1   20030624  (10)

                               NUMBER         DATE
                         ------------------ --------
PRIORITY INFORMATION:    US 2002-392512P    20020628 (60)
DOCUMENT TYPE:           Utility
FILE SEGMENT:            APPLICATION
LEGAL REPRESENTATIVE:    PAUL G. LUNN, ESQ. NASTECH PHARMACEUTICAL COMPANY,
                         INC., 3450 MONTE VILLA PARKWAY, BOTHELL, WA, 98021-8906
NUMBER OF CLAIMS:        92
EXEMPLARY CLAIM:         1
NUMBER OF DRAWINGS:      4 Drawing Page(s)
LINE COUNT:              13170
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB       Compositions and methods are provided that include a biologically active
         agent and a permeabilizing agent effective to enhance mucosal delivery
         of the biologically active agent in a mammalian subject. The
         permeabilizing agent reversibly enhances mucosal epithelial paracellular
         transport, typically by modulating epithelial junctional structure
         and/or physiology at a mucosal epithelial surface in the subject. This
         effect typically involves inhibition by the permeabilizing agent of
         homotypic or heterotypic binding between epithelial membrane adhesive
         proteins of neighboring epithelial cells. Target proteins for this
         blockade of homotypic or heterotypic binding can be selected from
         various related junctional adhesion molecules (JAMs), occludins, or
         claudins. The permeabilizing agent is typically a peptide or peptide
         analog or mimetic, often selected or derived from an extracellular
         domain of a mammalian JAM, occludin or claudin protein.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9   ANSWER 2 OF 5  USPATFULL on STN
ACCESSION NUMBER:        2004:38077  USPATFULL
TITLE:                   Dopamine agonist formulations for enhanced central
                         nervous system delivery
```

INVENTOR(S): Quay, Steven C., Edmonds, WA, UNITED STATES
PATENT ASSIGNEE(S): Nastech Pharmaceutical Company Inc, Hauppauge, NY (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004028613	A1	20040212	
APPLICATION INFO.:	US 2001-891630	A1	20010625	(9)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834
NUMBER OF CLAIMS: 58
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Page(s)
LINE COUNT: 8045
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Pharmaceutical formulations are described comprising at least one dopamine receptor agonist and one or more mucosal delivery-enhancing agents for enhanced mucosal delivery of the dopamine receptor agonist. In one aspect, the mucosal delivery formulations and methods provide enhanced delivery of the dopamine receptor agonist to the central nervous sytstem (CNS), for example by yielding dopamine receptor agonist concentrations in the cerebral spinal fluid of 5% or greater of the peak dopamine agonist concentrations in the blood plasma following administration to a mammalian subject. Exemplary formulations and methods within the invention utilize apomorphine as the dopamine receptor agonist. Other exemplary methods and formulations focus in intranasal administration of a dopamine receptor agonist. The formulations and methods of the invention are useful for treating a variety of diseases and conditions in mammalian subjects, including Parkinson's disease, male erectile dysfunction, female sexual dysfunction, among others. In alternate aspects, the mucosal delivery formulations and methods of the invention include one, or any combination of, mucosal delivery-enhancing agents selected from (a) aggregation inhibitory agents; (b) charge modifying agents; (c) pH control agents; (d) degradative enzyme inhibitors; (e) mucolytic or mucus clearing agents; (f) ciliostatic agents; (g) membrane penetration-enhancing agents; (h) modulatory agents of epithelial junction physiology; (i) vasodilator agents; (j) selective transport-enhancing agents; and (k) stabilizing delivery vehicles, carriers, supports or complex-forming agents. These methods and formulations of the invention provide for significantly enhanced absorption of dopamine receptor agonists into or across a nasal mucosal barrier to a target site of action, for example the CNS.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 3 OF 5 USPATFULL on STN
ACCESSION NUMBER: 2004:31772 USPATFULL
TITLE: Antisense modulation of apaf-1 expression
INVENTOR(S): Zhang, Hong, Carlsbad, CA, UNITED STATES
Watt, Andrew T., Vista, CA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004023914	A1	20040205	
APPLICATION INFO.:	US 2003-399214	A1	20030825	(10)
	WO 2001-US32116		20011015	

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: LICATA & TYRRELL P.C., 66 E. MAIN STREET, MARLTON, NJ, 08053

NUMBER OF CLAIMS: 19
EXEMPLARY CLAIM: 1
LINE COUNT: 4160
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Antisense compounds, compositions and methods are provided for modulating the expression of Apaf-1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targetd to nucleic acids encoding Apaf-1. Methods of using these compounds for modulation of Apaf-1 expression and for treatment of diseases associated with expression of Apaf-1 are provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 4 OF 5 USPATFULL on STN
ACCESSION NUMBER: 2003:30295 USPATFULL
TITLE: Particles with improved solubilization capacity
INVENTOR(S): Anderson, David, Colonial Heights, VA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003022242	A1	20030130	
APPLICATION INFO.:	US 2002-176112	A1	20020621	(10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-300476P	20010623 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: WHITHAM, CURTIS & CHRISTOFFERSON, P.C., 11491 SUNSET HILLS ROAD, SUITE 340, RESTON, VA, 20190
NUMBER OF CLAIMS: 204
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Page(s)
LINE COUNT: 3885
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A particle is disclosed that comprises a first volume of hydrophobe-rich material with tunable dissolution and solubilization characteristics and a distinct second volume of nanostructured nonlamellar liquid crystalline material, said second volume containing said first domain and being capable of being in equilibrium with said first volume. Preferably, the nanostructured nonlamellar liquid crystalline material is capable of being in equilibrium with a polar solvent or a water-immiscible solvent or both.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 5 OF 5 USPATFULL on STN
ACCESSION NUMBER: 2002:275941 USPATFULL
TITLE: Antisense modulation of Apaf-1 expression
INVENTOR(S): Watt, Andrew T., Vista, CA, United States
PATENT ASSIGNEE(S): ISIS Pharmaceuticals, Inc., Carlsbad, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6468795	B1	20021022	
APPLICATION INFO.:	US 2000-690364		20001016	(9)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: LeGuyader, John L.
ASSISTANT EXAMINER: Schmidt, M
LEGAL REPRESENTATIVE: Licata & Tyrrell P.C.
NUMBER OF CLAIMS: 26

EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 4074
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Antisense compounds, compositions and methods are provided for modulating the expression of Apaf-1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Apaf-1. Methods of using these compounds for modulation of Apaf-1 expression and for treatment of diseases associated with expression of Apaf-1 are provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d l8 1-11 ibib abs

L8 ANSWER 1 OF 11 USPATFULL on STN
ACCESSION NUMBER: 2005:43474 USPATFULL
TITLE: New non-phospholipid lipid vesicles (nplv) and their use in cosmetic, therapeutic and prophylactic applications
INVENTOR(S): Wallach, Donald F.H., Geneve, SWITZERLAND

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2005037200	A1	20050217	
APPLICATION INFO.:	US 2004-493546	A1	20041015	(10)
	WO 2002-EP11607		20021016	

	NUMBER	DATE
PRIORITY INFORMATION:	EP 2001-402737	20011022

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: BROWDY AND NEIMARK, P.L.L.C., 624 NINTH STREET, NW, SUITE 300, WASHINGTON, DC, 20001-5303
NUMBER OF CLAIMS: 44
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Page(s)
LINE COUNT: 1412
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention concerns new lipid vesicles wherein all said lipids are non phospholipid lipids, methods of preparation thereof as well as their use as vehicle particularly in therapeutic applications such as prevention of AIDS.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 2 OF 11 USPATFULL on STN
ACCESSION NUMBER: 2004:258641 USPATFULL
TITLE: COATED PARTICLES, METHODS OF MAKING AND USING
INVENTOR(S): Anderson, David, Colonial Heights, VA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004201117	A1	20041014	
APPLICATION INFO.:	US 2003-624498	A1	20030723	(10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2002-170237, filed on 13 Jun 2002, GRANTED, Pat. No. US 6638621
Continuation-in-part of Ser. No. US 2000-297997, filed on 16 Aug 2000, GRANTED, Pat. No. US 6482517
Continuation-in-part of Ser. No. WO 1998-US18639, filed on 8 Sep 1998, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	WO 1998-US18639	19980908
	US 1997-58309P	19970909 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: WHITHAM, CURTIS & CHRISTOFFERSON, P.C., 11491 SUNSET HILLS ROAD, SUITE 340, RESTON, VA, 20190
NUMBER OF CLAIMS: 67
EXEMPLARY CLAIM: CLM-1-107
NUMBER OF DRAWINGS: 11 Drawing Page(s)
LINE COUNT: 5395
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A particle coated with a nonlamellar material such as a nonlamellar crystalline material, a nonlamellar amorphous material, or a nonlamellar semi-crystalline material includes an internal matrix core having at least one a nanostructured liquid **phase**, or at least on nanostructured liquid crystalline **phase** or a combination of the two is used for the delivery of active agents such as pharmaceuticals, nutrients, pesticides, etc. The coated particle can be fabricated by a variety of different techniques where the exterior coating is a nonlamellar material such as a nonlamellar crystalline material, a nonlamellar amorphous material, or a nonlamellar semi-crystalline material

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 3 OF 11 USPATFULL on STN
ACCESSION NUMBER: 2004:101671 USPATFULL
TITLE: Compositions and methods for modulating physiology of epithelial junctional adhesion molecules for enhanced mucosal delivery of therapeutic compounds
INVENTOR(S): Quay, Steven C., Edmonds, WA, UNITED STATES
PATENT ASSIGNEE(S): Nastech Pharmaceutical Company Inc. (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004077540	A1	20040422	
APPLICATION INFO.:	US 2003-601953	A1	20030624	(10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-392512P	20020628 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: PAUL G. LUNN, ESQ. NASTECH PHARMACEUTICAL COMPANY, INC., 3450 MONTE VILLA PARKWAY, BOTHELL, WA, 98021-8906
NUMBER OF CLAIMS: 92
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Page(s)
LINE COUNT: 13170
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods are provided that include a biologically active agent and a permeabilizing agent effective to enhance mucosal delivery of the biologically active agent in a mammalian subject. The permeabilizing agent reversibly enhances mucosal epithelial paracellular transport, typically by modulating epithelial junctional structure and/or physiology at a mucosal epithelial surface in the subject. This effect typically involves inhibition by the permeabilizing agent of homotypic or heterotypic binding between epithelial membrane adhesive proteins of neighboring epithelial cells. Target proteins for this blockade of homotypic or heterotypic binding can be selected from

various related junctional adhesion molecules (JAMs), occludins, or claudins. The permeabilizing agent is typically a peptide or peptide analog or mimetic, often selected or derived from an extracellular domain of a mammalian JAM, occludin or claudin protein.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 4 OF 11 USPATFULL on STN

ACCESSION NUMBER:	2004:38077 USPATFULL
TITLE:	Dopamine agonist formulations for enhanced central nervous system delivery
INVENTOR(S):	Quay, Steven C., Edmonds, WA, UNITED STATES
PATENT ASSIGNEE(S):	Nastech Pharmaceutical Company Inc, Hauppauge, NY (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004028613	A1	20040212	
APPLICATION INFO.:	US 2001-891630	A1	20010625	(9)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834
NUMBER OF CLAIMS:	58
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	1 Drawing Page(s)
LINE COUNT:	8045

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Pharmaceutical formulations are described comprising at least one dopamine receptor agonist and one or more mucosal delivery-enhancing agents for enhanced mucosal delivery of the dopamine receptor agonist. In one aspect, the mucosal delivery formulations and methods provide enhanced delivery of the dopamine receptor agonist to the central nervous sytstem (CNS), for example by yielding dopamine receptor agonist concentrations in the cerebral spinal fluid of 5% or greater of the peak dopamine agonist concentrations in the blood plasma following administration to a mammalian subject. Exemplary formulations and methods within the invention utilize apomorphine as the dopamine receptor agonist. Other exemplary methods and formulations focus in intranasal administration of a dopamine receptor agonist. The formulations and methods of the invention are useful for treating a variety of diseases and conditions in mammalian subjects, including Parkinson's disease, male erectile dysfunction, female sexual dysfunction, among others. In alternate aspects, the mucosal delivery formulations and methods of the invention include one, or any combination of, mucosal delivery-enhancing agents selected from (a) aggregation inhibitory agents; (b) charge modifying agents; (c) pH control agents; (d) degradative enzyme inhibitors; (e) mucolytic or mucus clearing agents; (f) ciliostatic agents; (g) membrane penetration-enhancing agents; (h) modulatory agents of epithelial junction physiology; (i) vasodilator agents; (j) selective transport-enhancing agents; and (k) stabilizing delivery vehicles, carriers, supports or complex-forming agents. These methods and formulations of the invention provide for significantly enhanced absorption of dopamine receptor agonists into or across a nasal mucosal barrier to a target site of action, for example the CNS.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 5 OF 11 USPATFULL on STN

ACCESSION NUMBER:	2004:31772 USPATFULL
TITLE:	Antisense modulation of apaf-1 expression
INVENTOR(S):	Zhang, Hong, Carlsbad, CA, UNITED STATES

Watt, Andrew T., Vista, CA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004023914	A1	20040205	
APPLICATION INFO.:	US 2003-399214	A1	20030825	(10)
	WO 2001-US32116		20011015	

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: LICATA & TYRRELL P.C., 66 E. MAIN STREET, MARLTON, NJ, 08053
NUMBER OF CLAIMS: 19
EXEMPLARY CLAIM: 1
LINE COUNT: 4160
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Antisense compounds, compositions and methods are provided for modulating the expression of Apaf-1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targetd to nucleic acids encoding Apaf-1. Methods of using these compounds for modulation of Apaf-1 expression and for treatment of diseases associated with expression of Apaf-1 are provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 6 OF 11 USPATFULL on STN
ACCESSION NUMBER: 2003:159130 USPATFULL
TITLE: Coated particles, methods of making and using
INVENTOR(S): Anderson, David M., Colonial Heights, VA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003108743	A1	20030612	
	US 6638621	B2	20031028	
APPLICATION INFO.:	US 2002-170237	A1	20020613	(10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2000-297997, filed on 16 Aug 2000, GRANTED, Pat. No. US 6482517
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: WHITHAM, CURTIS & CHRISTOFFERSON, P.C., 11491 SUNSET HILLS ROAD, SUITE 340, RESTON, VA, 20190
NUMBER OF CLAIMS: 107
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 11 Drawing Page(s)
LINE COUNT: 5538
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A particle coated with a nonlamellar material such as a nonlamellar crystalline material, a nonlamellar amorphous material, or a nonlamellar semi-crystalline material includes an internal matrix core having at least one a nanostructured liquid **phase**, or at least on nanostructured liquid crystalline **phase** or a combination of the two is used for the delivery of active agents such as pharmaceuticals, nutrients, pesticides, etc. The coated particle can be fabricated by a variety of different techniques where the exterior coating is a nonlamellar material such as a nonlamellar crystalline material, a nonlamellar amorphous material, or a nonlamellar semi-crystalline material

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 7 OF 11 USPATFULL on STN
ACCESSION NUMBER: 2003:30295 USPATFULL
TITLE: Particles with improved solubilization capacity
INVENTOR(S): Anderson, David, Colonial Heights, VA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003022242	A1	20030130	
APPLICATION INFO.:	US 2002-176112	A1	20020621	(10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-300476P	20010623 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: WHITHAM, CURTIS & CHRISTOFFERSON, P.C., 11491 SUNSET HILLS ROAD, SUITE 340, RESTON, VA, 20190
NUMBER OF CLAIMS: 204
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Page(s)
LINE COUNT: 3885
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A particle is disclosed that comprises a first volume of hydrophobe-rich material with tunable dissolution and solubilization characteristics and a distinct second volume of nanostructured nonlamellar liquid crystalline material, said second volume containing said first domain and being capable of being in equilibrium with said first volume. Preferably, the nanostructured nonlamellar liquid crystalline material is capable of being in equilibrium with a polar solvent or a water-immiscible solvent or both.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 8 OF 11 USPATFULL on STN
ACCESSION NUMBER: 2002:303798 USPATFULL
TITLE: Coated particles, methods of making and using
INVENTOR(S): Anderson, David M., Petersburg, VA, United States
PATENT ASSIGNEE(S): Select Release, L.C., Midlothian, VA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6482517	B1	20021119	
	WO 9912640		19990318	
APPLICATION INFO.:	US 2000-297997		20000816	(9)
	WO 1998-US18639		19980908	
			20000816	PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-58309P	19970909 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Boykin, Terressa M.
LEGAL REPRESENTATIVE: Whitham, Curtis & Christofferson, P.C.
NUMBER OF CLAIMS: 116
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 8 Drawing Figure(s); 8 Drawing Page(s)
LINE COUNT: 4264
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A particle coated with a nonlamellar crystalline material includes an internal matrix core having at least one nanostructured liquid **phase**, or at least one nanostructured liquid crystalline **phase** or a combination of the two is used for the delivery of active agents such as pharmaceuticals, nutrients, pesticides, etc. The coated particle can be fabricated by a variety of different techniques where the exterior coating is a nonlamellar crystalline material.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 9 OF 11 USPATFULL on STN
ACCESSION NUMBER: 2002:275941 USPATFULL
TITLE: Antisense modulation of Apaf-1 expression
INVENTOR(S): Watt, Andrew T., Vista, CA, United States
PATENT ASSIGNEE(S): ISIS Pharmaceuticals, Inc., Carlsbad, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6468795	B1	20021022
APPLICATION INFO.:	US 2000-690364		20001016 (9)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: LeGuyader, John L.
ASSISTANT EXAMINER: Schmidt, M
LEGAL REPRESENTATIVE: Licata & Tyrrell P.C.
NUMBER OF CLAIMS: 26
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 4074
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Antisense compounds, compositions and methods are provided for modulating the expression of Apaf-1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Apaf-1. Methods of using these compounds for modulation of Apaf-1 expression and for treatment of diseases associated with expression of Apaf-1 are provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 10 OF 11 EPFULL COPYRIGHT 2005 EPO/FIZ KA on STN

ACCESSION NUMBER: 2001:150671 EPFULL
DATA UPDATE DATE: 20040114
DATA UPDATE WEEK: 200403
TITLE (ENGLISH): New non-phospholipid lipid vesicles (npLV) and their use in cosmetic, therapeutic and prophylactic applications
TITLE (FRENCH): Vesicles non-phospholipidiques (npLV) et leur utilisation en cosmetique, therapeutique et preventive
TITLE (GERMAN): Non-phospholipid Vesikel (npLV) und ihre Verwendung in kosmetischen, therapeutischen und prophylaktischen Anwendungen
INVENTOR(S): Wallach, Donald F. H., 38 A route de Malagnou, 1208, Geneva, CH
PATENT APPLICANT(S): Wallach, Donald F. H., 38 A route de Malagnou, 1208, Geneva, CH
PATENT APPL. NUMBER: 3923050
AGENT: Santarelli, 14, avenue de la Grande Armee, 75017 Paris, FR
AGENT NUMBER: 100891
LANGUAGE OF FILING: English
LANGUAGE OF PUBL.: English
LANGUAGE OF PROCEDURE: English
LANGUAGE OF TITLE: German; English; French
DOCUMENT TYPE: Patent
PATENT INFO TYPE: EPA1 Application published with search report
PATENT INFORMATION:

NUMBER	KIND	DATE

	EP 1304103	A1	20030423
DESIGNATED STATES:	DE FR GB NL		
APPLICATION INFO.:	EP 2001-402737	A	20011022
PRIORITY INFO.:	EP 2001-402737	A	20011022 *

ABEN

The present invention concerns new lipid vesicles wherein all said lipids are non phospholipid lipids, methods of preparation thereof as well as their use as vehicle particularly in therapeutic applications such as prevention of AIDS.

L8 ANSWER 11 OF 11 EPFULL

ACCESSION NUMBER:	1998:74237 EPFULL
DATA UPDATE DATE:	20040721
DATA UPDATE WEEK:	200430
TITLE (ENGLISH):	COATED PARTICLES, METHODS OF MAKING AND USING
TITLE (FRENCH):	PARTICULES ENROBEES, PROCEDES DE FABRICATION ET D'UTILISATION
TITLE (GERMAN):	BESCHICHTETE TEILCHEN, METHODE ZU IHRER HERSTELLUNG UND VERWENDUNG
INVENTOR(S):	ANDERSON, David, M., 103 Croatan Circle, Cary, NC 27513, US
PATENT APPLICANT(S):	Lyotropic Therapeutics, Inc., 10487 Lake Ridge Parkway, Ashland, VA 23005, US
PATENT APPL. NUMBER:	4125332
AGENT:	Wagner, Karl H., Dipl.-Ing., et al, WAGNER & GEYER Patentanwaelte Gewuerzmuehlstrasse 5, 80538 Muenchen, DE
AGENT NUMBER:	12561
LANGUAGE OF FILING:	English
LANGUAGE OF PUBL.:	English
LANGUAGE OF PROCEDURE:	English
LANGUAGE OF TITLE:	German; English; French
DOCUMENT TYPE:	Patent
PATENT INFO TYPE:	EPB1 Granted patent
PATENT INFORMATION:	
PATENT INFORMATION:	

NUMBER	KIND	DATE
NUMBER	KIND	DATE
EP 942780	B1	20030730
WO 9912640		19990318
DESIGNATED STATES:	AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE	
APPLICATION INFO.:	EP 1998-950618 A	19980908
	WO 1998-US18639 A	19980908
PRIORITY INFO.:	US 1997-58309P P	19970909
CITED PATENT LIT.:	WO 9306921 A	
	US 4344857 A	
	US 5039559 A	
	US 5407609 A	
	US 5543158 A	
	US 5679377 A	
	US 5785976 A	